View source for Tezosentan

{{orphan|date=February 2009}}
{{Drugbox
| IUPAC_name        = ''N''-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2''H''-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide
| image             =  Tezosentan.png
| CAS_number        = 
| CAS_supplemental  =
| ATC_prefix        = none
| ATC_suffix        = 
| ATC_supplemental  = 
| PubChem           = 151174
| DrugBank          = 
| chemical_formula  = 
| C=27 | H=27 | N=9 | O=6 | S=1 
| molecular_weight  = 605.624
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Tezosentan''' is a non-selective [[Endothelin receptor type A|ET<sub>A</sub>]] and [[Endothelin receptor type B|ET<sub>B</sub>]] [[Endothelin receptor antagonist|receptor antagonist]].<ref name=Urbanowicz> {{cite journal |last=Urbanowicz |first=W |authorlink= |coauthors=Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D |year=2004 |month= |title=Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats |journal=Gut |volume=53 |issue= 12|pages=1844–1849 |id= |url=http://gut.bmj.com/cgi/content/abstract/53/12/1844 |accessdate= |quote= publisher= BMJ Publishing Group Ltd & British Society of Gastroenterology|doi=10.1136/gut.2003.036517 |pmid=15542526 |pmc=1774327}}</ref> It acts as a vasodilator and was designed as a therapy for patients with acute [[heart failure]].  Recent studies have shown however, that tezosentan does not improve [[dyspnea]] or reduce the risk of fatal or nonfatal cardiovascular events.<ref name=news-med>{{cite web |url=http://www.news-medical.net/?id=32315 |title=Tezosentan does not appear to improve symptoms for patients with acute heart failure |accessdate=2007-11-24 |author= |date= 7-Nov-2007 |work= Medical Studies/Trials |publisher=news-medical.net}} </ref>

== References ==
{{reflist}}

[[Category:Vasodilators]]
[[Category:Tetrazoles]]
[[Category:Pyridines]]
[[Category:Pyrimidines]]
[[Category:Phenol ethers]]
[[Category:Sulfonamides]]
[[Category:Alcohols]]

{{pharma-stub}}
[[Category:2Fix]]